These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 39103259

  • 1. [Prostate cancer with BRCA2 pathogenic mutation: a clinicopathological analysis].
    Wang DH, Yin WL, Pan XY, Zhang MN, Nie L, Chen XQ, Zeng H, Zhou Q, Chen N.
    Zhonghua Bing Li Xue Za Zhi; 2024 Aug 08; 53(8):789-796. PubMed ID: 39103259
    [Abstract] [Full Text] [Related]

  • 2. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM.
    Eur Urol; 2015 Mar 08; 67(3):496-503. PubMed ID: 25154392
    [Abstract] [Full Text] [Related]

  • 3. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.
    Prostate; 2018 Apr 08; 78(5):401-407. PubMed ID: 29368341
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical and oncologic findings of extraprostatic extension on needle biopsy in de novo metastatic prostate cancer.
    Chen JR, Zhao JG, Zhu S, Zhang MN, Chen N, Liu JD, Sun GX, Shen PF, Zeng H.
    Asian J Androl; 2020 Apr 08; 22(4):427-431. PubMed ID: 31424026
    [Abstract] [Full Text] [Related]

  • 6. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB, Kirichek AA, Filippova MG, Savinkova AV, Khalmurzaev OA, Lyubchenko LN.
    Urologiia; 2019 Dec 08; (5):79-85. PubMed ID: 31808637
    [Abstract] [Full Text] [Related]

  • 7. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A, Kavanagh L, Clouston D, Bolton D, kConFab Investigators, Fox S, Thorne H.
    BJU Int; 2012 Dec 08; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [Abstract] [Full Text] [Related]

  • 8. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
    Zhao JG, Nie L, Chen XQ, Chen N, Zeng H.
    Zhonghua Wai Ke Za Zhi; 2019 Jun 01; 57(6):422-427. PubMed ID: 31142066
    [Abstract] [Full Text] [Related]

  • 9. Germline BLM mutations and metastatic prostate cancer.
    Ledet EM, Antonarakis ES, Isaacs WB, Lotan TL, Pritchard C, Sartor AO.
    Prostate; 2020 Feb 01; 80(2):235-237. PubMed ID: 31816118
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.
    Prostate Cancer Prostatic Dis; 2019 Sep 01; 22(3):406-410. PubMed ID: 30542053
    [Abstract] [Full Text] [Related]

  • 12. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
    Cussenot O, Timms KM, Perrot E, Blanchet P, Brureau L, Solimeno C, Fromont G, Comperat E, Cancel-Tassin G.
    Eur Urol Oncol; 2024 Jun 01; 7(3):597-604. PubMed ID: 38182487
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC).
    Custodio-Cabello S, Pacheco-Barcia V, Palka-Kotlowska M, Fernández-Hernández L, Del Álamo JF, Oliveros-Acebes E, Cabezón-Gutiérrez L.
    Urol Oncol; 2024 Oct 01; 42(10):331.e13-331.e24. PubMed ID: 38926076
    [Abstract] [Full Text] [Related]

  • 14. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
    Cui M, Gao XS, Gu X, Guo W, Li X, Ma M, Qin S, Qi X, Xie M, Peng C, Bai Y.
    Oncotarget; 2017 Jun 20; 8(25):40222-40232. PubMed ID: 28410213
    [Abstract] [Full Text] [Related]

  • 15. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.
    Nat Commun; 2017 Jan 09; 8():13671. PubMed ID: 28067867
    [Abstract] [Full Text] [Related]

  • 16. A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M.
    Pathol Int; 2019 Dec 09; 69(12):715-720. PubMed ID: 31631483
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    Zhao J, Sun G, Zhu S, Dai J, Chen J, Zhang M, Ni Y, Zhang H, Shen P, Zhao X, Zhang B, Pan X, Nie L, Yin X, Liang J, Zhang X, Wang Z, Zhu X, Liao B, Liu Z, Armstrong CM, Gao AC, Huang H, Chen N, Zeng H.
    BJU Int; 2022 Mar 09; 129(3):345-355. PubMed ID: 34185954
    [Abstract] [Full Text] [Related]

  • 19. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES.
    Mod Pathol; 2021 Jun 09; 34(6):1185-1193. PubMed ID: 33462368
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.
    Eur Urol; 2019 Aug 09; 76(2):170-176. PubMed ID: 30293905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.